Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,825
  • Shares Outstanding, K 20,767
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,890 K
  • 60-Month Beta 0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.84
Trade ADIL with:

Options Overview Details

View History
  • Implied Volatility 131.55%
  • Historical Volatility 80.97%
  • IV Percentile 86%
  • IV Rank 44.72%
  • IV High 199.33% on 09/15/21
  • IV Low 76.71% on 10/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 374
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 25
  • Open Int (30-Day) 134

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.47 +4.45%
on 11/29/21
3.52 -26.70%
on 11/18/21
-0.57 (-18.10%)
since 11/02/21
3-Month
2.47 +4.45%
on 11/29/21
5.08 -49.21%
on 09/24/21
-1.73 (-40.14%)
since 09/02/21
52-Week
1.60 +61.25%
on 12/29/20
5.08 -49.21%
on 09/24/21
+0.59 (+29.65%)
since 12/02/20

Most Recent Stories

More News
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer

PNV2 demonstrates reduction of metastases in animal model...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments

CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options

Financing to support clinical trial pathway for non-opioid drug candidate for treatment of pain...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments

CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors

CHARLOTTESVILLE, Va., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain

Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction ...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as Drug Candidate for the Treatment of Pain

Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction ...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

CHARLOTTESVILLE, Va., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021

CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...

ADIL : 2.56 (-3.03%)
ADILW : 0.7201 (-2.69%)
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be...

CLGN : 17.49 (-0.57%)
NLSP : 1.69 (-15.50%)
TGCB : 0.7000 (+6.06%)
OSS.VN : 0.570 (-1.72%)
OSSIF : 0.4400 (-1.12%)
MITI : 0.1685 (-9.21%)
AYRO : 2.12 (+2.42%)
IMAC : 1.2301 (-0.80%)
CR : 98.06 (+3.80%)
MYO : 7.76 (-2.51%)
BASA : 0.2201 (-11.96%)
ADIL : 2.56 (-3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 3.13
2nd Resistance Point 3.01
1st Resistance Point 2.83
Last Price 2.56
1st Support Level 2.53
2nd Support Level 2.41
3rd Support Level 2.23

See More

52-Week High 5.08
Fibonacci 61.8% 3.75
Fibonacci 50% 3.34
Fibonacci 38.2% 2.93
Last Price 2.56
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar